Peer-reviewed veterinary case report
Higher filaggrin enzyme activity found in dogs with atopic dermatitis
By Fanton, Natalia et al.·Published in Veterinary dermatology·2017·Clinica Veterinaria San Siro, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Increased filaggrin-metabolizing enzyme activity in atopic skin: a pilot study using a canine model of atopic dermatitis.
- Species:
- dog
Plain-English summary
A group of beagles with skin allergies (atopic dermatitis) showed higher levels of certain enzymes that help break down a protein important for skin health compared to healthy dogs. Researchers took skin samples from both groups before and after exposing them to allergens to see how these enzymes behaved. The study found that the allergic dogs had significantly more of these enzymes right from the start, indicating a problem with their skin barrier. This suggests that dogs with skin allergies might struggle more with skin hydration and protection.
People also search for: dog skin allergies treatment · beagle atopic dermatitis symptoms · why is my dog itching · dog skin barrier problems · enzymes in dog skin health
Abstract
BACKGROUND: Filaggrin (FLG) and its metabolites are essential for skin barrier function and hydration of the stratum corneum. Alteration of the FLG metabolism could be the basis for an abnormal skin barrier in allergic dogs. OBJECTIVES: To investigate the expression and distribution of calpain-1, caspase-14, furin and matriptase, four enzymes involved in FLG metabolism, in the skin of atopic and healthy beagles. METHODS: Skin biopsies were collected from four healthy and four atopic beagles before and after allergen exposure. The dogs were challenged for three consecutive days to mimic an acute exposure, or once weekly to mimic a chronic exposure to allergens. Skin biopsies were taken on days 0 (nonlesional), 3 and 10 in the "acute" model and on days 0 (nonlesional), 14 and 28 in the "chronic" model. Four healthy dogs were used as controls. Indirect immunofluorescence was used to analyse the distribution and the expression of FLG enzymes in a semi-quantitative manner. Five consecutive pictures/section were taken and the intensity analysed tracing the epidermis and using ImageJ on the traced areas. The enzymes' expression was compared between healthy and atopic nonlesional skin (Day 0) and over time in each group. RESULTS: All enzymes were expressed in all layers of the epidermis. A significantly higher expression of calpain-1 (P = 0.028), caspase 14 (P = 0.028) and matriptase (P = 0.028) was evident in atopic compared to control dogs on Day 0. No differences over time were seen for any enzyme analysed. CONCLUSIONS AND CLINICAL IMPORTANCE: This preliminary study suggests an abnormal catabolism of FLG in canine atopic skin.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28393458/